NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

照護現場 (POC) 分子診斷市場與未來性

The Market and Future Potential for Molecular Point of Care

出版商 Kalorama Information 商品編碼 1006563
出版日期 內容資訊 英文 115 Pages
商品交期: 最快1-2個工作天內
價格
照護現場 (POC) 分子診斷市場與未來性 The Market and Future Potential for Molecular Point of Care
出版日期: 2021年01月22日內容資訊: 英文 115 Pages
簡介

照護現場 (POC) 分子診斷系統,比實驗室為基礎的檢驗快,比現有的照護現場 (POC) 系統更正確設計。新系統的開發與現有線的選單不斷增加。

本報告提供照護現場 (POC) 分子診斷市場與未來的可能性調查分析,發展與趨勢,市場分析,主要企業等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 照護現場 (POC) 分子診斷市場發展與趨勢

  • 照護現場 (POC) 分子診斷的優點和缺點
  • MPOC系統的投資
  • 新興適應

第3章 市場分析

  • 照護現場 (POC) 分子診斷市場分析
  • "NPT分子診斷" 市場

第4章 企業簡介

  • ABBOTT LABORATORIES
  • AIDIAN OY
  • AKONNI BIOSYSTEMS
  • BINX HEALTH, INC.
  • BIOCARTIS NV
  • BIOMERIEUX SA
  • CEPHEID
  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology/Genetics Testing
  • CREDO BIOSCIENCE
  • CURETIS NV
  • DIASORIN S.P.A
  • GENMARK DIAGNOSTICS
  • GREINER BIO-ONE GMBH
  • MERIDIAN BIOSCIENCE, INC.
  • MESA BIOTECH, INC.
  • QIAGEN NV
  • QUANTUMDX GROUP
  • QUIDEL CORPORATION
  • ROCHE
  • SEKISUI DIAGNOSTICS LLC
  • T2 BIOSYSTEMS
目錄
Product Code: 21-014

This report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings. Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting.

Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems. Development of new systems and menu expansion on existing lines is constant. Kalorama Information defines molecular point of care or mPOC as consisting of devices marketed to customers outside the reference lab that run PCR or other DNA and RNA testing on a device with a small footprint. mPOC systems tend to have a result time fast enough for an office visit or bedside consultation. These systems feature cartridges or reduced preparation steps and limited interpretation of test results.

This was a subset of the testing industry still proving its merit to customers early last year, but certainly the COVID-19 pandemic has been an influence on the market, as we suggested in the last report. The ability to deliver rapid PCR results has put them in the right place with the right function at the right time. This report features a complete update on mPOC and COVID-19. It also discusses other growth areas.

The data in “The Market and Future Potential for Molecular Point of Care” includes information on systems and competitor analysis, as well as data on the size and growth of the market:

  • Current Molecular POC Systems
  • Molecular Point of Care Market: 2020-2025
  • COVID mPOC Market
  • Molecular Point of Care Market Share by Vendor, 2020 ($M, %)
  • Small-Footprint Molecular Point of Care Market, 2020 (%)
  • Geographic Breakout of the Molecular Point of Care Market, 2020 (N. America, Europe, APAC, RoW)
  • Segment Breakout of Molecular Point of Care Market, 2020 (Respiratory vs. Other)
  • Breakout of Molecular Point of Care Market, 2020 (%; Respiratory, Other)
  • Respiratory Segment Breakout, 2020 (Flu, RSV, Strep, Other)
  • Breakout of mPOC Respiratory, 2020 (%; Flu, Strep, RSV, Other)
  • Near Patient Molecular IVD Market: 2020-2025
  • Near Patient Molecular Market Share by Vendor, 2020
  • Company Profiles

Many trends are covered in the report, including menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC and other trends.

Companies profiled include:

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMérieux SA
  • Cepheid
  • Credo Bioscience
  • Curetis NV
  • DiaSorin S.p.A
  • GenMark Diagnostics
  • Greiner Bio-One GmbH
  • Meridian Bioscience, Inc.
  • Mesa Biotech, Inc.
  • QIAGEN NV
  • QuantuMDx Group
  • Quidel Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

  • WHERE IS MOLECULAR POINT OF CARE IN 2021?
  • MOLECULAR POINT OF CARE MARKET ANALYSIS
    • Table 1-1: Molecular Point of Care Market: 2019-2024
    • Figure 1-1: mPOC Market by Disease Indication, 2019 (%; Respiratory, Other)
    • Market Observations
    • "Near-Patient" Molecular Systems Market
      • Table 1-2: Near Patient Molecular Systems Market: 2019-2024
  • CURRENT TRENDS
  • COVID-19 and mPOC
  • MOLECULAR POINT-OF-CARE DIAGNOSTICS DEFINED
    • USAGE OF MOLECULAR POINT OF CARE
    • LEADING MPOC PLATFORMS
      • Table 1-3: Market-Available Molecular POC Diagnostic Platforms
    • TRENDS
  • SCOPE AND METHODOLOGY

CHAPTER TWO: MOLECULAR POINT-OF-CARE MARKET DEVELOPMENT AND TRENDS

  • ADVANTAGES AND DISADVANTAGES OF MOLECULAR POINT OF CARE
    • Table 2-1: Disadvantages of Molecular Point of Care, by Setting
    • JUSTIFICATION: THE SENSITIVITY/SPECIFICITY ARGUMENT
    • NEW SYSTEMS AND MENU EXPANSION
      • Table 2-2: Recent Menu Expansions for Hospital and POC Molecular Platforms (Vendor, Platform, Menu Addition, Time to Results, CLIA-waiver, US/EU Availability)
  • INVESTMENT IN MPOC SYSTEMS
    • CHINA AS A POC MARKET
    • COMMON TESTS AND ANALYTES IN POC DIAGNOSTICS
    • COMPONENT TECHNOLOGIES OF MOLECULAR POINT-OF-CARE DIAGNOSTICS
    • Microfluidics
    • qPCR
    • Microarrays
    • Isothermal Amplification
    • Test Automation
    • Primers and Probes
    • Detection
    • Next-Generation Sequencing
    • MOLECULAR DIAGNOSTICS
    • Real-Time PCR (qPCR)
    • Isothermal Amplification Methods
    • Line Probe Assays
    • Next-Generation Sequencing
    • APPLICATIONS AND POTENTIAL APPLICATIONS FOR MOLECULAR POINT-OF-CARE
    • COVID-19
    • Major Testing Applications for Molecular POC Diagnostics
    • Influenza
    • Hospital-Acquired Infections (HAIs)
    • Strep A
    • Respiratory Syncytial Virus (RSV)
  • EMERGING APPLICATIONS
    • Other Respiratory Infections
    • Group B Streptococcus
    • STDs
    • Tuberculosis
    • Malaria
    • Other Tropical and Neglected Diseases
    • Cancer
    • EUROPEAN DEVICE REGULATIONS NEARING

CHAPTER THREE: MARKET ANALYSIS

  • MOLECULAR POINT OF CARE MARKET ANALYSIS
    • Table 3-1: Molecular Point of Care Market: 2019-2024
    • Table 3-2: Molecular Point of Care Market Share by Vendor, 2019 ($M, %)
    • Figure 3-1: Small-Footprint Molecular Point of Care Market, 2019 (%)
    • Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2019 (N. America, Europe, APAC, RoW)
    • Table 3-4: Segment Breakout of Molecular Point of Care Market, 2019 (Respiratory vs. Other)
    • Figure 3-2: Breakout of Molecular Point of Care Market, 2019 (%; Respiratory, Other)
    • Respiratory Molecular Point of Care Segmentation
      • Table 3-5: Respiratory Segment Breakout, 2019 (Flu, RSV, Strep, Other)
      • Figure 3-3: Breakout of mPOC Respiratory, 2019 (%; Flu, Strep, RSV, Other)
  • "NEAR PATIENT MOLECULAR" MARKET
    • Table 3-6: Near Patient Molecular IVD Market: 2019-2024
    • Market Share Near Patient
      • Table 3-7: Near Patient Molecular Market Share by Vendor, 2019

CHAPTER FOUR: COMPANY PROFILES

  • ABBOTT LABORATORIES
  • AIDIAN OY
  • AKONNI BIOSYSTEMS
  • BINX HEALTH, INC.
  • BIOCARTIS NV
  • BIOMÉRIEUX SA
  • CEPHEID
  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology/Genetics Testing
  • CREDO BIOSCIENCE
  • CURETIS NV
  • DIASORIN S.P.A
  • GENMARK DIAGNOSTICS
  • GREINER BIO-ONE GMBH
  • MERIDIAN BIOSCIENCE, INC.
  • MESA BIOTECH, INC.
  • QIAGEN NV
  • QUANTUMDX GROUP
  • QUIDEL CORPORATION
  • ROCHE
  • SEKISUI DIAGNOSTICS LLC
  • T2 BIOSYSTEMS